A study was undertaken to determine whether impotence in some diabetic patients might be due to a coincidental prolactinoma and therefore be potentially treatable. Of 83 consecutive men attending a diabetic clinic, three were found to have persistent mild to moderate hyperprolactinaemia. None of the three was impotent or taking any drug known to be associated with elevated serum prolactin, and anterior pituitary responses and pituitary fossa tomograms did not reveal any abnormality. The mean serum prolactin concentration of the 37 insulin-treated men was not significantly different from that of the 46 men on diet with or without anti-diabetic tablets, nor was there any significant difference between the mean serum prolactin concentrations of the 19 impotent men and of the 64 non-impotent men.
Hyperprolactinaemia has been found to be associated with impotence in some non-diabetic men. 1 -3 Impotence is widely regarded as a common concomitant of diabetes mellitus.s " Neuropathy, angiopathy, testicular deficiency, and psychological factors have all been implicated but no single specific cause has emerged. The present study was undertaken to determine whether impotence in some diabetic patients might also be due to hyperprolactinaemia associated with pituitary tumours and therefore potentially treatable with bromocriptine.
Patients and methods
Eighty-three consecutive male patients aged 15-60 years attending the diabetic clinic were studied. They answered an interview-administered questionnaire about their libido and potency or, if they did not have a sexual partner, whether they experienced morning erections. No attempt was made to validate the questionnaire, and results are based on patients' own assessments of their sexual performance. Blood for serum prolactin measurement was taken by venepuncture with the random blood glucose that is taken at the beginning of every clinic attendance. The samples were separated and the serum was stored at -20°C. They were assayed together at the end of the study using the prolactin assay developed for the North East Thames Regional Immunoassay Scheme." This uses as antiserum rabbit antihuman prolactin (P4/577) and as tracer human prolactin radioiodinated using solid phase lactoperoxidase. Both the antiserum and the prolactin were obtained from Dr P Lowry. The assay buffer is 0'05 M phosphate buffer, pH 7·4, containing 2· 5% bovine serum albumin. Standards are prepared from a high prolactin serum pool and calibrated against the MRC 75/504 International reference preparation.
In diabetic patients who were impotent, autonomic neuropathy was assessed by examination for postural hypotension and electrocardiography during deep respiration to detect reduction of normal sinus arrhythmia. 7 The mean ages, duration of diabetes, and prolactin levels of the impotent and non-impotent groups were compared by means of Student's t test.
Results
The Figure 
Table I Mean ages, duration of diabetes, and serum prolactin concentrations in impotent and non-impotent subjects
moderately elevated prolactin levels of 510 770 and 8~0 mU/1 in the original samples (normal'rangf or this assay up to 360 mU/1), and these were still elevated at 580, 660, and 1080 mU/I, respectively, on subsequent testing up to six months later. The first of these three patients was 49 years old and not im?otent. I:Ie~as taking chlorpropamide, 250 mg da~ly, for his diabetes and also carbimazole, 10 mg daily for thyrotoxicosis. His slightly elevated prolactin may have been due to stress. We took no specific precautions in our study to exclude stress since our diabetic patients are accustomed to both hospital clinic routine and venepuncture. The degree of hyperprolactinaemia in his case, however, was not thought to be sufficient to warrant further investigations. The second patient was 48 years old not im.potent, and was taking chlorpropamide, 250 mg dally. The third was 50 years old and sometimes experienced difficulty in achieving erections. He was taking metformin 850 rng twice daily, for his diabetes. The pituitary function of the latter two patients was assessed. Both had normal responses to insulin, thyrotrophin-releasing hormone, and gonadotrophin-releasing hormone, and tomograms of their pituitary fossae were normal. In the absence of any clear clinical indications it was felt unjustifiable to administer bromocriptine to either.
Almost a quarter of the patients, 19 of 83, admitted to impotence on direct questioning, although only three. had previously sought help for sexual dysfunction, In Table 1 the mean ages, duration of diabetes, and prolactin levels of the impotent and non-impotent groups are compared. The impotent group was significantly older than the non-impotent group (r = 3·260, P<0'05), but there was no significant difference between the mean duration of diabetes and serum prolactin concentrations of the two groups. Table 2 shows the diabetic treatment of the two groups. The majority of impotent subjects were taking oral hypoglycaemic agents for their diabetes whereas the majority of non-impotent subjects were on insulin. This finding probably relates to the older age of the impotent subjects.
The mean serum prolactin concentration of the 37 insulin-treated men was 210 (SD ± 76) mU/1. This was not significantly different from the mean level of 204 (SD ± 143) mU /1 of the 46 non-insulintreated men. All 19 impotent diabetics were examined for clinical evidence of autonomic neuropathy. Only one, aged 31, had postural hypotension and a significant reduction in sinus arrythmia on deep respiration.
Discussion
There have been conflicting reports of prolactin levels in diabetic subjects. Hunter and his coworkers found high mean random prolactin levels in 10 diabetic patients without retinopathy with normal levels in four patients with retinopathy. 8 Other groups, however, have found normal basal prolactin concentrations in insulin-dependent diabetic men with or without retinopathy.v-'! We found no difference in the mean serum prolactin concentration in insulin and non-insulintreated diabetic patients, and 80 of our 83 patients had levels within the normal range. None of the three men with slight or moderately elevated levels was taking any medicine known to be associated with elevated prolactin levels. None was impotent and none had galactorrhoea.
Most non-diabetic men with impotence associated with prolactinomas have grossly elevated prolactin levels. In the series of Franks et al.,2 however, four of the 17 impotent men with prolactinomas and three of the four men with normal potency and prolactinomas had modest elevation in serum prolactin concentration comparable with those of our three patients. In a study of prolactin status in 921 subjects, three of 16 patients with prolactinomas had elevated levels comparable with those of our patients.P However, there were also 10 women with so-called idiopathic hyperprolactinaemia in whom no factor could be found to account for persistently elevated prolactin levels. It remains to be seen whether our patients develop detectable prolactinomas or whether they represent a male group with idiopathic hyperprolactinaemia.
Since diabetes mellitus is such a common disorder it is likely that there are occasional diabetic men suffering from impotence which is due to a prolactinoma. There is a danger that because impotence is widely regarded as a frequent complication of diabetes mellitus a potentially treatable condition might go undetected. We have shown that specific diabetic impotence may be very uncornmon-P and suggest that diabetic men who complain of impotence should be investigated in the same way as non-diabetics.
